Abstract: Clinical development of immune checkpoint inhibitors targeting the PD-1 pathway has led to clinical benefits for patients with multiple solid tumor and hematologic malignancies and has revolutionized modern oncology. High response rates to PD-1 blockade in patients with classical Hodgkin lymphoma and certain subtypes of non-Hodgkin lymphoma highlight an intrinsic biologic sensitivity to this strategy of treatment. Despite early success of checkpoint inhibitor and immunomodulatory drug combinations in phase 2 studies in multiple myeloma, safety concerns in patients treated with the combination of immunomodulatory drugs and checkpoint inhibitors in myeloma have stalled drug development in this space. Novel combination approaches exploring PD-1 inhibitors with epigenetic modifiers in leukemia are underway.
A s the key mediators of host immunosurveillance, effector T cells are tasked with the maintenance of host immune homeostasis through elimination of intracellular pathogens and neoplasia while also minimizing autoimmune responses and collateral damage to host tissues. At the level of the tissue microenvironment, T-cell activation or inhibition requires costimulatory or coinhibitory signaling after T-cell receptor recognition of its cognate peptide presented in the context of major histocompatibility complex (MHC) I or II receptor on the cell surface. A host of costimulatory and coinhibitory ligand-receptor interactions known as immune checkpoints then ultimately determine T-cell fate within the spectrum of activation or inhibition by modulating a balance between expansion, exertion of cellular cytotoxicity, and memory formation versus anergy, exhaustion, or senescence. 1 Clinical development of monoclonal antibodies that block immune checkpoints cytotoxic T-lymphocyte antigen 4, PD-1 receptor, and PD-L1 has resulted in Food and Drug Administration approvals for use of these agents in multiple solid and hematologic tumors. Herein, we focus on the current status of clinical development of PD-1 pathway inhibitors for the treatment of hematologic malignancies.
THE PD-1 PATHWAY

Biology of PD-1 and Its Ligands PD-L1 (B7-H1) and PD-L2 (B7-DC)
PD-1 receptor (PD-1, CD279) is a type I transmembrane immunoreceptor expressed by activated T cells, natural killer (NK) cells, and B cells cells. [2] [3] [4] To prevent immune-related damage to self after binding of TCR to MHC-peptide, T cell activation is inhibited through binding of PD-1 on T cells to its ligands PD-L1 (B7-H1, CD274) and/or PD-L2 (B7-DC, CD273) that are normally expressed on peripheral tissues. PD-1 ligands PD-L1 and PD-L2 are known to be expressed in the tumor microenvironment by both tumor cells 2, 5 and non-tumor immune and stromal cells.
2,4-8
Binding of PD-1 to its ligands act to inhibit cytotoxic T cell activity via an intracellular signaling cascade involving several kinases downstream of PD-1. 9 Continued PD-1 signaling is important in development of T cell exhaustion, a state in which T cells lose their capacity for cytotoxicity. 10 Antitumor activity following blockade of the PD-1 axis suggests PD-1 signaling is important for immune escape and tumor persistence, an idea supported by clinical efficacy of PD-1 pathway blockade in multiple tumor types and several hematologic cancers.
PDL1 is encoded on the long arm of chromosome 9p under the control of an activator protein-1 (AP-1) sensitive promoter region downstream of JAK-2-STAT signaling cascade. Expression of PD-L1 is upregulated by many cytokines, most potently by interferon-γ (IFN-γ). 6 Interferon-mediated upregulation of PD-L1 and PD-L2 is an important feature of several hematologic cancers that reside in a pro-inflammatory tumor microenvironment, including acute myeloid leukemia 11 and multiple myeloma. 12, 13 In addition to cytokine-mediated mechanisms of inducible PD-L1 overexpression, oncogenic viruses relevant to lymphomagenesis such as EBV are directly capable of driving PD-L1 expression via downstream effects of latent membrane protein-1 (LMP-1) on nuclear factor kappa B (NF-κB) signaling and the AP-1 sensitive promoter of PD-L1.
14,15 PD-L1 can also be overexpressed by STAT3 upregulation via upstream activation of ALK. 16 Correlative analysis of ongoing trials in hematologic malignancies is needed to explore the contribution of these and other mechanisms to response and resistance to PD-1 pathway inhibition.
CLASSICAL HODGKIN LYMPHOMA (cHL)
Early-phase clinical trials of PD-1 pathway blockade highlighted that certain lymphomas, especially classical Hodgkin lymphoma (cHL), harbor an intrinsic susceptibility to PD-1 pathway blockade. Hodgkin lymphoma is defined by the presence of the Hodgkin Reed Sternberg cell among a robust inflammatory infiltrate and is cured with chemotherapy or combined-modality therapy in most cases. However, a need exists for patients with cHL who relapse or are refractory to existing therapies. In several preclinical studies in cHL, near universal overexpression of PD-L1 on the Hodgkin Reed Sternberg cell likely driven by 9p24.1 amplification were noted, suggesting a biologic importance to the PD-1 pathway in cHL. 17 Supporting the importance of PD-1 signaling to the pathogenesis of cHL, a significant efficacy signal was apparent in the phase 1 clinical trials of nivolumab (Opdivo, Bristol-Myers Squibb), a humanized IgG1 kappa monoclonal antibody, and pembrolizumab (Keytruda, Merck), a humanized IgG4 kappa monoclonal antibody, both of which block the interaction of PD-1 with its ligands PD-L1 and PD-L2. Responses to PD-1 blockade were directly related to the degree of amplification of 9p24.1. 18 In the CheckMate039 phase 1 clinical trial (nivolumab), relapsed/refractory (R/R) patients with cHL had an overall response rate (ORR) of 87%, with 17% reaching a complete response (CR), and 70% with a partial response (PR). 19, 20 Among 31 patients with cHL with relapse after brentuximab vedotin (BV) and autologous stem cell transplantation (ASCT) or prior ineligibility for treatment with BV, the ORR was 58%, the CR rate was 19%, and the PR rate was 12%, with median follow-up of 24.9 months. 21 The phase 2 study of pembrolizumab, KEYNOTE-087, evaluated 210 patients among three cohorts, in whom the overall response rate was 69%, and the overall CR rate was 22.4%. 22 The ORR was 73.9% in R/R patients with cHL with progressive lymphoma after ASCT and BV, 64.2% in patients with chemoresistant disease ineligible for ASCT, and 70.0% in BV-naive patients with relapsed disease after ASCT. These important studies led the Food and Drug Administration (FDA) to grant accelerated approval to nivolumab and pembrolizumab for the treatment of Hodgkin lymphoma.
Ongoing studies are evaluating use of PD-1 blockade for cHL in the frontline setting and in a variety of patient populations including those who are transplant ineligible, early-stage unfavorable disease, and in patients older than 60. Interim results from a phase 1/2 study of nivolumab plus BVas first salvage after upfront chemotherapy before ASCT showed a CR rate of 63% among 59 patients, a rate much higher than expected with either agent as a monotherapy. 23 In sum, PD-1 pathway blockade is very likely to transform the treatment landscape for patients with cHL in the coming years.
NON-HODGKIN LYMPHOMA (NHL)
Substantial heterogeneity exists among non-Hodgkin lymphomas. Within this large group of malignancies, there have been some responses to PD-1 pathway blockade. PD-L1 up-regulation via genetic aberrations involving 9p24.1 is found commonly in primary mediastinal B-cell lymphoma, 24 primary testicular lymphoma, 25 plasmablastic lymphoma, human herpesvirus 8-associated primary effusion lymphoma, and primary central nervous system lymphomas 25, 26 ; and several of these tumors have been sensitive to PD-1 blockade. Promising activity of pembrolizumab for primary mediastinal B-cell lymphoma was observed in a phase 1b study with 41% responding to treatment among 17 patients. 24 Chronic viral infection with EBV also plays a role in PD-L1 upregulation, and high response rates to PD-1 blockade in extranodal NK/T-cell lymphoma, 27 EBV(+) and EBV(−) lymphoproliferative disorders have been reported.
Diffuse large B-cell lymphoma (DLBCL) represents a heterogeneous group of aggressive malignancies derived from mature B lymphocytes. A retrospective series of 1253 samples from patients with DLBCL showed that only 11% were PD-L1 positive and those patients with PD-L1 had a poor prognosis. 28 In addition, patients with DLBCL with a high International Prognostic Index score and elevated soluble PD-L1 (sPD-L1) have an inferior prognosis, with a 3-year overall survival of 40.9% in patients with high sPD-L1 compared with 82.1% in those without elevated sPD-L1. 29 In a signal-seeking phase 1b study, 36% of unselected patients with DLBCL responded to treatment with nivolumab. 30 PD-1 can also be up-regulated on peripheral T-cell lymphomas derived from T follicular helper cells including angioimmunoblastic T-cell lymphoma, follicular T-cell lymphoma, and nodal peripheral T-cell lymphoma with T follicular helper cell phenotype. 31 A phase 2 study in mycosis fungoides/Sézary syndrome demonstrated a response rate of 38% in 24 patients. 32 Evaluation for biomarkers predictive of response to PD-1 pathway blockade in lymphoma may aid in optimal patient selection for prospective clinical trials. Markers of immune exhaustion LAG-3 (lymphocyte activation gene 3) and TIM-3 (T-cell immunoglobulin and mucin-domain containing-3) have been found to be coexpressed in T-cell infiltrates in NHL, and these may represent viable targets alone or in combination with PD-1 blockade. 33, 34 Biomarkers of poor response to therapy also warrant attention; beta-2 microglobulin mutations and loss of MHC-I expression are relevant in melanoma resistant to PD-1 pathway blockade. 35 Correlation of these biomarkers with outcome after checkpoint blockade in cHL or NHL has not yet been reported, although it is known that beta-2 microglobulin mutations and loss of MHC-II are frequent findings in cHL.
MULTIPLE MYELOMA
Multiple myeloma (MM) is a clonally heterogeneous hematologic malignancy derived from terminally differentiated B cells known as plasma cells, which secrete clonal monoclonal immunoglobulin paraproteins and whose effects in the bone marrow tumor microenvironment cause systemic multifactorial cellular and humoral immunodeficiency. The MM bone marrow tumor microenvironment is characterized by profound immunosuppression related to inhibitory cytokines, [36] [37] [38] [39] [40] suppressive cells such as myeloid-derived suppressor cells, 41, 42 and regulatory T cells [43] [44] [45] and known active PD-1/PD-L1 signaling. 12 In contrast to plasma cells in premalignant states, MM cells express PD-L1 driven by IFN-γ, toll-like receptor, Akt, and Ras signaling, 12, 46 and its expression is functionally associated with reduced susceptibility to effector T-cell killing.
12 PD-1 is expressed on marrow-infiltrating T cells, and PD-1 ligands are expressed and up-regulated on malignant plasma cells in MM. 47 Multifactorial immunosuppression within the MM tumor microenvironment inhibits MM-specific tumor-infiltrating T cells, which retain the capacity for recognizing and killing MM cells ex vivo, suggestive of a potential benefit to reversing local immunosuppression in the tumor microenvironment. 47 A large retrospective study recently found that patients with MM with a high mutational and neoantigen burden in MM have inferior progression-free survival and outcomes, 48 a potentially provocative result given that sensitivity to immune checkpoint blockade was observed among patients with high-mutation burden solid tumors.
Despite evidence suggesting importance of the PD-1 pathway in MM, there was no clinical activity seen in the 27 patients treated with nivolumab on the CheckMate 039 study. 30 Preclinical data supported a synergistic role for immunomodulatory drugs (IMiDs) with PD-1 pathway blockade in patients with myeloma, as IMiDs polarize T cells toward a T H 1 phenotype and promote NK-cell cytotoxicity, 42 ,49 inhibit regulatory T cells, 50 and down-regulate PD-L1 on tumor cells. 42, 49 Preliminary results of PD-1 pathway blockade combined with IMiDs were encouraging. The phase 1 study of pembrolizumab with lenalidomide and dexamethasone (KEYNOTE-023, NCT02036502) showed a response to therapy in 20 of 40 evaluable patients (ORR, 50%) with 5 patients reaching very good partial response and 14 patients achieving PR. 51 In the lenalidomide-refractory patients, the ORR to pembrolizumab plus lenalidomide and dexamethasone was 38% (11/29) . 51 In patients with detectable bone marrow plasma cells by flow cytometry, 100% expressed PD-L1, whereas PD-L2 expression was variable. 51 The phase 2 study of pembrolizumab plus pomalidomide and dexamethasone showed an ORR of 60%, with 8% of patients achieving a strict complete remission. In patients previously refractory to both proteasome inhibitors and IMiDs, the response rate was 68%. 52 Building on these results, 2 phase 3 studies of pembrolizumab in combination with lenalidomide and dexamethasone (KEYNOTE-185, NCT02579863) or pomalidomide and dexamethasone (KEYNOTE-183, NCT02576977) and one phase 3 study of pomalidomide and dexamethasone versus nivolumab, pomalidomide, and dexamethasone versus nivolumab, elotuzumab, pomalidomide, and dexamethasone (CheckMate 602, NCT02726581) were initiated. However, on June 12, 2017, after a review of data by the studies' data monitoring committee, the FDA requested a stop to new accrual to these studies owing to increased patient deaths on the trial arms receiving experimental therapy with pembrolizumab in combination with IMiDs lenalidomide or pomalidomide. 53 An investigation of the nature of these deaths are underway; and on July 3, 2017, the FDA required that further treatment be discontinued for all patients on these trials 54 Interim analysis of the KEYNOTE-183 data using a data cutoff date of June 2 showed a higher relative risk of death for patients in these studies receiving pembrolizumab plus pomalidomide and dexamethasone over pomalidomide and dexamethasone (hazard ratio, 1.61, [95% confidence interval, 0.91-2.85]), and an objective response rate of 34% compared to 40% in the control arm. 55 In the KEYNOTE-185 study, the hazard ratio of the pembrolizumabcontaining investigational arm was 2.06 (95% confidence interval, 0.93-4.55), and an ORR of 64% in the investigational arm compared with ORR 62% in the control arm. 55 Until further analysis can be performed, other studies including PD-1-and PD-L1-blocking antibodies in myeloma have been placed on hold by the FDA as a precaution. 54 In addition, durvalumab trials in combination with immunomodulatory agents in patients with chronic lymphocytic leukemia (CLL) or lymphoma were also placed on hold. 56 The pembrolizumab phase 3 results in MM highlight a critical need to explore immune regulation at the interface between malignant plasma cells and the tumor microenvironment. Further analysis and follow-up of patients accrued to both the pembrolizumab and other IMiD/anti-PD-1 or anti-PD-L1 trials will hopefully elucidate if there are patient or disease factors that predict for benefit or toxicity of this therapy in MM.
LEUKEMIA PD-1 pathway blockade is currently under exploration for treatment of myeloid hematologic cancers, often in combination with other epigenetic and immunomodulatory agents. In contrast to lymphoma, there have been limited clinical results reported to date of PD-1 pathway blockade in patients with leukemia. However, preclinical data suggest a potential role for the PD-1 pathway in patients with myeloid malignancies. In myelodysplastic syndromes (MDS), PD-L1 is expressed by CD34+ blasts in a significant subset of patient samples (~36%), whereas stroma and nonblast cellular components express PD-1. 57 In acute myeloid leukemia (AML), PD-L1 expression on AML cells is negatively correlated with outcome. [57] [58] [59] Although PD-L1 expression is low on most cases of de novo AML, IFN-induced PD-L1 expression increases on AML blast cells during treatment, and PD-L1 expression is higher in patients with relapsed AML than in de novo patients. 11, 58, 60 Preclinical mouse models also point toward the PD-1/PD-L1 pathway in immune evasion by AML. [61] [62] [63] [64] Hypomethylating agents up-regulate immune checkpoints, 57 further suggesting an appealing treatment strategy of combination epigenetic therapy and immunotherapy for myeloid malignancies. Hypomethylating agents also trigger expression of endogenous retroviruses in multiple human tumor types, activating a cellular viral defense program mediated by interferon-β, and strongly potentiating checkpoint blockade in mouse models. 65, 66 A phase 2 study is underway in MDS evaluating nivolumab or ipilimumab combined with 5-azacitidine. 67 Nivolumab as a single agent had no activity in MDS, but early data showed an overall response rate of 69% for combination azacitidine and nivolumab in patients previously failing azaciditine. 67 Preliminary clinical data for nivolumab in combination with azacitidine in patients with relapsed or refractory AML also suggest a promising ORR of 34% (N=53) in this high-risk patient population. 67 There are several trials underway evaluating nivolumab in combination with other agents in precursor B acute lymphoblastic leukemia (B-ALL) (NCT02879695) and AML (NCT 02532231). Pembrolizumab trials are underway in B acute lymphoblastic leukemia and T acute lymphoblastic leukemia (NCT02767934), AML (transplant-ineligible) (NCT02771197), and R/R chronic lymphocytic leukemia (NCT02332980).
TOXICITY AND IMMUNE-RELATED ADVERSE EVENTS
Immune checkpoint blockade has been clearly associated with unique immune-mediated toxicities. With single-agent therapy, the adverse effect profile in hematologic malignancies has been similar to that seen in patients with solid tumor; and adverse effects can be readily reversed with established algorithms for immunosuppression. Specific consideration to overlapping toxicities in combination studies of PD-1 pathway blockade and drugs routinely used in hematologic malignancies are beyond the scope of this review. Nevertheless, therapies that cause pneumonitis, such as radiation, BV, bleomycin for treatment of Hodgkin disease, and IMiDs for treatment of MM highlight some of the potential challenges of discerning causality in the face of toxicity.
Another specific scenario is in the setting of stem cell transplantation, a therapy unique to hematologic cancer. Several preclinical studies demonstrated augmentation of graft-versustumor effects 68, 69 and graft-versus-host-disease (GVHD). 70 After 4 treatment-related deaths were noted among 39 patients receiving PD-1 blockade before allogeneic hematopoietic stem cell transplantation (allo-HSCT), the FDA added a warning to the package insert for nivolumab, 71 urging vigilance for early evidence of GVH after allo-HSCT such as severe acute GVHD, hepatic veno-occlusive disease, steroid-responsive febrile syndromes that my precede GVHD, and other immune-related phenomena. 47 There are limited data to support use of PD-1 antibodies after allo-HSCT, and off-label use in this manner is increasing in frequency. 72 Three retrospective series report that the high response rate to treatment with PD-1 blockade after allo-HSCT (ORR, 77%-95%) was accompanied by a rate of severe treatment emergent GVHD of 30% to 55%. [72] [73] [74] A prospective trial of PD-1 blockade as a maintenance therapy after allo-HSCT is ongoing (NCT02985554).
CONCLUSIONS
Successes in cHL and subtypes of NHL have led to a surge of investigation into the potential benefits of PD-1 pathway blockade in distinct cohorts of patients with lymphoma. Development of PD-1/PD-L1 blockade in myeloma has been halted for the moment by safety issues that demand thoughtful scrutiny to protect patients and inform future clinical trials. Drug development of PD-1 in leukemia is underway with limited results to date, although preliminary data suggest that combination epigenetic therapy and PD-1 blockade may have some efficacy in myeloid malignancies. Safety issues have also been raised in the context of allogeneic SCT. These observations highlight a multitude of disease-specific challenges facing investigators seeking to treat cancers of immune cell origins with therapies that potently modulate the immune response.
Successes in immune checkpoint blockade have also fueled enthusiasm for other novel immunotherapies such as adoptive T-cell therapy with chimeric antigen receptor T cells, novel antibody engineering products such as bispecific T-cell engager proteins, and tumor vaccines or immunotherapies directed at shared tumor antigens or patient-specific neoantigens. Development of novel biomarkers predictive of response and failure of these therapies in hematologic malignancies is critical to expanding the number of patients who derive durable benefits and to evaluate for rationale to combine with immune checkpoint blockade in search of durable remissions or cures for a greater number of patients.
